Transdermal administration to humans and animals
First Claim
1. A pharmaceutical composition for use in the transdermal administration of a medicament, whereby said medicament is detectable in the bloodstream within two hours after administration, which composition comprisesa medicament adapted for transdermal administration and a pharmaceutically acceptable carrier for the medicament;
- the improvement being that the carrier consists essentially of at least one compound selected from the group consisting of esters of C8-24 fatty acids with at least one aliphatic hydroxy compound containing 2-12 carbon atoms and 2-3 hydroxy groups and the acid component of the ester is selected from caprylic, capric, lauric palmic, stearic, arachidic, behenic, lignoceric, oleic, claidic, petroselinic, linoleic, alpha-linolenic, (9,12,15-octadecatrienoic acid), gamma-linolenic, linolelaidic, arachidic, 11-eicosenoic, 11,14-eicosadienoic, 11,14,17-eicosatrienoic, 8,11,14-eicosatrienoic, arachidonic, 5,8,11,14,17-eicosapentaenoic, erucic and nervonic acids, provided that when said hydroxy compound is glycerol, the esters thereof are selected from diglycerides and triglycerides of at least one C8-24 fatty acid.
2 Assignments
0 Petitions
Accused Products
Abstract
A pharmaceutical composition for use in the transdermal administration of a medicament to both humans and animals, which composition comprises at least ingredients (1) and (2) of the following ingredients (1), (2) and (3), namely: (1) an effective amount of a medicament adapted for transdermal administration; (2) a transdermally transporting effective amount of a carrier for the medicament, which carrier is selected from semisolids and liquids at ambient temperatures, and which carrier comprises at least one compound selected from esters of C8-24 fatty acids, pharmaceutically acceptable aliphatic polyhydroxy compounds and non-volatile paraffins; (3) an optional medicament selected from antiinflammatory agents and antihistamines, effective to mitigate any skin-incompatibility characteristic which may otherwise be present. Administration is preferably by means of a matrix which comprises a porous, absorbent, perforate and flexible laminar solid support, having the composition absorbed thereon. The invention includes a device for use in transdermal administration, which comprises such a matrix, preferably included in a multilayer system providing a desired controlled or sustained release pattern for said medicament; as well as apparatus for applying a medicament non-adhesively to the skin of an animal, which comprises a removable enclosure bearing such a matrix or device, the apparatus being arranged for non-invasive mounting onto an animal ear.
112 Citations
8 Claims
-
1. A pharmaceutical composition for use in the transdermal administration of a medicament, whereby said medicament is detectable in the bloodstream within two hours after administration, which composition comprises
a medicament adapted for transdermal administration and a pharmaceutically acceptable carrier for the medicament; - the improvement being that the carrier consists essentially of at least one compound selected from the group consisting of esters of C8-24 fatty acids with at least one aliphatic hydroxy compound containing 2-12 carbon atoms and 2-3 hydroxy groups and the acid component of the ester is selected from caprylic, capric, lauric palmic, stearic, arachidic, behenic, lignoceric, oleic, claidic, petroselinic, linoleic, alpha-linolenic, (9,12,15-octadecatrienoic acid), gamma-linolenic, linolelaidic, arachidic, 11-eicosenoic, 11,14-eicosadienoic, 11,14,17-eicosatrienoic, 8,11,14-eicosatrienoic, arachidonic, 5,8,11,14,17-eicosapentaenoic, erucic and nervonic acids, provided that when said hydroxy compound is glycerol, the esters thereof are selected from diglycerides and triglycerides of at least one C8-24 fatty acid.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
Specification